Mutational processes shape the landscape of TP53 mutations in human cancer.
Nat Genet.
2018;
Giacomelli AO,, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP,,, Takeda DY,,, Ly SH,, Kim E, Gannon HS,, Hurhula B, Sharpe T, Goodale A, Fritchman B, Steelman S, Vazquez F,, Tsherniak A, Aguirre AJ,, Doench JG, Piccioni F, Roberts CWM,,, Meyerson M,,, Getz G,,,, Johannessen CM, Root DE, Hahn WC,,,.
| Products/Services Used |
Details |
Operation |
| Codon Optimization |
The EM7 promoter and TP53 coding sequence bearing an amber stop codon were synthesized (GenScript) in-frame with the Sh ble gene, which confers Zeocin resistance51. |
Get A Quote |
Unlike most tumor suppressor genes, the most common genetic alterations in tumor protein p53 (TP53) are missense mutations1,2. Mutant p53 protein is often abundantly expressed in cancers and specific allelic variants exhibit dominant-negative or gain-of-function activities in experimental models3-8. To gain a systematic view of p53 function, we interrogated loss-of-function screens conducted in hundreds of human cancer cell lines and performed TP53 saturation mutagenesis screens in an isogenic pair of TP53 wild-type and null cell lines. We found that loss or dominant-negative inhibition of wild-type p53 function reliably enhanced cellular fitness. By integrating these data with the Catalog of Somatic Mutations ... More
Unlike most tumor suppressor genes, the most common genetic alterations in tumor protein p53 (TP53) are missense mutations1,2. Mutant p53 protein is often abundantly expressed in cancers and specific allelic variants exhibit dominant-negative or gain-of-function activities in experimental models3-8. To gain a systematic view of p53 function, we interrogated loss-of-function screens conducted in hundreds of human cancer cell lines and performed TP53 saturation mutagenesis screens in an isogenic pair of TP53 wild-type and null cell lines. We found that loss or dominant-negative inhibition of wild-type p53 function reliably enhanced cellular fitness. By integrating these data with the Catalog of Somatic Mutations in Cancer (COSMIC) mutational signatures database9,10, we developed a statistical model that describes the TP53 mutational spectrum as a function of the baseline probability of acquiring each mutation and the fitness advantage conferred by attenuation of p53 activity. Collectively, these observations show that widely-acting and tissue-specific mutational processes combine with phenotypic selection to dictate the frequencies of recurrent TP53 mutations.
